Ace inhibitors potently reduce vascular inflammation, results of an open proof-of-concept study in the abdominal aortic aneurysm

Lindeman, J.

doi:10.1016/j.atherosclerosis.2014.05.398

Cited by 2 publications

(1 citation statement)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In many studies ARBs and ACE-I have been shown to decrease OS and inflammation in hypertensive patients [ 21 , 22 ]. Both these parameters can affect lung pathologies.…”

Section: Discussionmentioning

confidence: 99%

Renin Angiotensin system-modifying therapies are associated with improved pulmonary health

Soto

Bang

McCombs

et al. 2017

Clin Diabetes Endocrinol

View full text Add to dashboard Cite

BackgroundPulmonary diseases are often complicated and have diverse etiologies. One common factor is the lack of therapeutics available for these diseases. The goal of this study was to investigate the impact of Renin-Angiotensin System (RAS)-modifying medications on incidence and time to pulmonary complications.MethodsA retrospective analysis was conducted using claims data from a US commercial insurance company (2007–2013). The study consisted of patients with an emerging hypertension (HTN) diagnosis. Cox analysis was used to look at the effect of angiotensin converting enzyme inhibitors (ACE-Is) and angiotensin receptor blockers (ARBs) in this population. The events included pneumonia and influenza (infectious), Chronic obstructive pulmonary disease (COPD) and allied conditions (inflammatory), and other diseases (structural).ResultsA total of 215,225 patients were followed in the study. These fell into three groups depending on the first prescribed anti-hypertension medication; ACE-Is (47.21%), ARBs (11.40%) and calcium channel blockers (CCBs)/Diuretics-Control (41.39%). The use of ACE-I as first treatment significantly reduced the incidence of infectious (Hazard Ratio (HR) 0.886, 95% Confidence Interval (95% CI) 0.859–0.886), inflammatory (HR 0.924, 95% CI 0.906–0.942) and structural outcomes (HR 0.865, 95% CI 0.847–0.885); it also increased the time (delayed) to diagnosis with prolonged treatment. Primary ARB use only significantly lowered the incidence of structural outcomes (HR 0.900, 95% CI 0.868–0.933); prolonged treatment did reduce incidence of all three diagnosis groups and significantly delayed disease onset.ConclusionsThere is an association between the use of ACE-Is and ARBs and a delay in the progression of pulmonary complications in vulnerable populations. Research into the RAS may identify future therapies for patients with potential chronic pulmonary conditions.

show abstract

“…In many studies ARBs and ACE-I have been shown to decrease OS and inflammation in hypertensive patients [ 21 , 22 ]. Both these parameters can affect lung pathologies.…”

Section: Discussionmentioning

confidence: 99%

Renin Angiotensin system-modifying therapies are associated with improved pulmonary health

Soto

Bang

McCombs

et al. 2017

Clin Diabetes Endocrinol

View full text Add to dashboard Cite

show abstract

The Role of Inflammation as a Preponderant Risk Factor in Cardiovascular Diseases

García

Asensio

Perdicaro

et al. 2022

CVP

View full text Add to dashboard Cite

Cardiovascular diseases cause considerable health and economic burden, as they are the leading cause of disability and death in the western world. Inactivity, hypertension, obesity, diabetes, and smoking are among the classic risk factors for cardiovascular disease. From a pathophysiological point of view, the arteries of our body bear the harmful stimuli produced by these factors and respond to them with a series of intricate adaptive mechanisms. Vascular remodeling constitutes an adaptive response to hemodynamic and inflammatory alterations associated with hypertension, diabetes, and other illnesses. Thickening of the arterial walls leads to endothelial dysfunction and increases the risk of cerebrovascular and coronary events. During the last decades, antiplatelet, lipid-lowering, and antihypertensive therapies have been the cornerstone of primary and secondary prevention of cardiovascular events. However, it is still unknown whether their efficacy is strictly associated with the control of the classical risk factors, or because of their additive effects on vascular inflammation. Since inflammation of arterial walls is related to the pathogenesis of atherosclerosis, it has been hypothesized that anti-inflammatory therapies could prevent and treat vascular remodeling. Clinical trials based on canakinumab or hydroxychloroquine provide further insight into the role of inflammation in the pathophysiology of cardiovascular diseases. In this review, we analyze previous evidence and suggest that inflammation may play an important role in the final pathway of many cardiovascular risk factors.

show abstract

Ace inhibitors potently reduce vascular inflammation, results of an open proof-of-concept study in the abdominal aortic aneurysm

Cited by 2 publications

References 34 publications

Renin Angiotensin system-modifying therapies are associated with improved pulmonary health

Renin Angiotensin system-modifying therapies are associated with improved pulmonary health

The Role of Inflammation as a Preponderant Risk Factor in Cardiovascular Diseases

Contact Info

Product

Resources

About